N-Benzhydrylacetamide Inhibitors of Jumanji Domain Histone Demethylases for Cancer Treatment
Summary
USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation covering substituted N-benzhydrylacetamide inhibitors of Jumanji domain histone demethylases for treating cancer via Wnt signaling pathway inhibition. The patent includes 10 claims and covers compounds according to Formula I and II, along with methods of administering these compounds to subjects needing cancer treatment.
What changed
USPTO granted patent US12599597B2 to the University of Kentucky Research Foundation for N-benzhydrylacetamide inhibitors targeting Jumanji domain histone demethylases, applicable to cancer treatment through Wnt signaling pathway inhibition. Inventors include Chunming Liu, David S. Watt, Wen Zhang, and Vitaliy M. Sviripa, with the application filed March 4, 2021. The patent covers compounds having structures according to Formula II and methods of administering Formula I and/or Formula II compounds to subjects requiring cancer treatment.
Pharmaceutical companies and research institutions seeking to develop or license histone demethylase inhibitors for oncology applications should monitor this patent portfolio. The granted patent establishes intellectual property protection for the assignee, potentially affecting freedom-to-operate considerations for competing therapeutic development programs targeting the Wnt signaling pathway in cancer treatment.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Substituted N-benzhydrylacetamide inhibitors of jumanji domain histone demethylases for the treatment of cancer
Grant US12599597B2 Kind: B2 Apr 14, 2026
Assignee
University of Kentucky Research Foundation
Inventors
Chunming Liu, David S. Watt, Wen Zhang, Vitaliy M. Sviripa
Abstract
Provided herein are compounds for inhibiting Wnt signaling and methods of treating cancer. The compounds include any compound having a structure according to Formula II. The method includes administering one or more compounds according to Formula I and/or Formula II to a subject in need thereof.
CPC Classifications
A61K 31/4709 A61K 31/47 A61P 35/00
Filing Date
2021-03-04
Application No.
17907943
Claims
10
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.